Regeneron Pharmaceuticals (LTS:0R2M) Cyclically Adjusted Book per Share: $171.87 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0R2M Regeneron Pharmaceuticals Inc LTS:0R2M
87 GF Score
Price $676.38
GF Value $910.39
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Regeneron Pharmaceuticals Cyclically Adjusted Book per Share?

Regeneron Pharmaceuticals LTS:0R2M +0.59% 87 Cyclically Adjusted Book per Share is $171.87 as of Mar. 2026. GuruFocus rates LTS:0R2M with a GF Score™ of 87/100 and a GF Value™ of $910.39 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $299.224. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $171.87 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Regeneron Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 20.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 23.80% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 28.80% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 31.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Regeneron Pharmaceuticals was 35.90% per year. The lowest was -4.00% per year. And the median was 16.15% per year.

As of today (2026-07-21), Regeneron Pharmaceuticals's current stock price is $676.38. Regeneron Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $171.87. Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 3.94.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regeneron Pharmaceuticals was 32.93. The lowest was 3.43. And the median was 9.95.


Regeneron Pharmaceuticals  (LTS:0R2M) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=676.38/171.87
=3.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Regeneron Pharmaceuticals was 32.93. The lowest was 3.43. And the median was 9.95.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Regeneron Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Regeneron Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Regeneron Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals Cyclically Adjusted Book per Share Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.02 84.96 109.25 134.07 163.73

Regeneron Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.45 149.20 159.70 163.73 171.87

LTS:0R2M vs ALNY, RVMD, ONC: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


LTS:0R2M
87GF Score
Regeneron Pharmaceuticals Inc LTS:0R2M
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regeneron Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Regeneron Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=299.224/330.2130*330.2130
=299.224

Current CPI (Mar. 2026) = 330.2130.

Regeneron Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 38.720 241.018 53.049
201609 42.586 241.428 58.247
201612 41.971 241.432 57.405
201703 45.791 243.801 62.021
201706 51.537 244.955 69.475
201709 56.345 246.819 75.383
201712 57.088 246.524 76.468
201803 60.896 249.554 80.578
201806 66.568 251.989 87.232
201809 72.713 252.439 95.115
201812 80.338 251.233 105.594
201903 86.188 254.202 111.960
201906 88.865 256.143 114.562
201909 95.736 256.759 123.124
201912 100.562 256.974 129.223
202003 108.146 258.115 138.354
202006 85.424 257.797 109.420
202009 94.965 260.280 120.481
202012 103.087 260.474 130.687
202103 112.308 264.877 140.011
202106 141.748 271.696 172.277
202109 159.058 274.310 191.473
202112 172.706 278.802 204.553
202203 181.858 287.504 208.873
202206 188.930 296.311 210.546
202209 197.048 296.808 219.225
202212 206.788 296.797 230.070
202303 214.177 301.836 234.313
202306 220.550 305.109 238.697
202309 228.863 307.789 245.537
202312 237.375 306.746 255.535
202403 244.959 312.332 258.983
202406 255.986 314.175 269.054
202409 266.316 315.301 278.911
202412 267.783 315.605 280.178
202503 271.562 319.799 280.405
202506 281.336 322.561 288.010
202509 293.949 324.800 298.848
202512 295.666 324.054 301.285
202603 299.224 330.213 299.224

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $171.87 mean?
Regeneron Pharmaceuticals (LTS:0R2M) has a Cyclically Adjusted Book per Share of $171.87 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors.
Is Regeneron Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Regeneron Pharmaceuticals' current Cyclically Adjusted Book per Share is $171.87. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Cyclically Adjusted Book per Share compare to ALNY and RVMD?
Regeneron Pharmaceuticals' Cyclically Adjusted Book per Share of $171.87 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Regeneron Pharmaceuticals and its competitors. Regeneron Pharmaceuticals's current Cyclically Adjusted Book per Share is $171.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $910.39, compared to a current price of $676.38 — trading 25.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is $171.87. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current Cyclically Adjusted Book per Share is $171.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?

Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued. The current stock price of $676.38 is trading 25.7% below its estimated GF Value™ of $910.39. GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for LTS:0R2M:

  • Cyclically Adjusted Book per Share: $171.87
  • GF Value™: $910.39 vs. price of $676.38 (25.7% below fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Regeneron Pharmaceuticals Business Description

Address 777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score

Get the complete analysis for LTS:0R2M

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$676.38
Price
$910.39
GF Value